MedImmune LLC [clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30]
Chris Ambrose, M.D. [clinicaltrials_resource:02366bf4848c9d0d94e13d840db21bc7]David Gossage, M.D., MBA [clinicaltrials_resource:02ca8cd842322334a49fed25e591063f]Gabor Illei, MD [clinicaltrials_resource:03154e44626f844a276715de35fcfe19]David E. Weng, M.D., PhD [clinicaltrials_resource:07cecfe4b450844d5ec7b4cdaa4611cf]MedImmune [clinicaltrials_resource:091204c33700a3bb92a726c26c1f3aa3]Robert Walker, MD [clinicaltrials_resource:0baa5968df6a49f44a8afb5bff2ab9e8]Dominique Ethgen, M.D. [clinicaltrials_resource:0c2a011209e2701072bc9fd17b3edcaa]Luz Hammershaimb, M.D. [clinicaltrials_resource:0e1165135e82c60d77d60b22bbe1ab2c]AstraZeneca Clinical Study Information Center [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]M Pamela Griffin, MD [clinicaltrials_resource:198bc8dfc8b624c8497e64b08efa72df]Joseph Sliman, M.D. [clinicaltrials_resource:1b506e414fd29eb52105694296d5826d]Trishna Goswami [clinicaltrials_resource:1c7c02d90e6230db4b00ff5bee59fd03]Joseph M. Parker, M.D. [clinicaltrials_resource:1d8a85b2befbf44160ce966392596fa4]Pamela Griffin, 301-398-0000 [clinicaltrials_resource:1df1e751a91609d5d042e4e1e4cf0dce]Judith Falloon, M.D. [clinicaltrials_resource:1f252bdcbcb554e8668460c75f7a072f]Hanaa Elhefni, MD, MS, MPH [clinicaltrials_resource:23a8143ba4393eab19cb3802cf169a3d]Ramy Ibrahim, Senior Director [clinicaltrials_resource:260aacc38df52d33a3fece858d9b59b5]Barbara White, M.D. [clinicaltrials_resource:2b839759747ff014ecfe7ba2f386aa86]Rayburn Mallory, M.D. [clinicaltrials_resource:2b862bd8b52fb97cb9afb4fac6883d0f]Ehsanollah Esfandiari, PhD MD [clinicaltrials_resource:3294c7d564d4e3f0de3f2628f4d69660]Judith Falloon, MD [clinicaltrials_resource:32a24093f88837faf563e0382bdac33c]Seth Toback, M.D. [clinicaltrials_resource:3626f9186c5abafc0d973c805389a6be]MedImmune, LLC [clinicaltrials_resource:391f7b8d3e7448f2703889a31b971935]Margarita Gomez, M.D. [clinicaltrials_resource:3ff8fd4f0d6226a4f07c195599d0fdeb]Warren Greth, M.D. [clinicaltrials_resource:42aee81a866fae9b06178fe74bb0f1db]Genevieve Losonsky, MD [clinicaltrials_resource:48c744933666277878c4b03d2c1c7d82]Genny Losonsky, MD [clinicaltrials_resource:4999aef6def045fe55d2a66b560f8bb1]Robert Walker, M.D. [clinicaltrials_resource:4e3a23189c86ce9d52ccb936b2895f8b]Donald Raible, MD [clinicaltrials_resource:5013246b0f8ec74a8d38a947ec8b2fa5]Pamela Griffin, M.D. [clinicaltrials_resource:504c60be02283705af14c8b0198745b2]Hason Jafri, M.D. [clinicaltrials_resource:511568db0e2f3bae7f7b49d0e5566c83]Edward Piper, M.D. [clinicaltrials_resource:532a54d62b0b09c7dc0e644cfe337aa4]Margarita Gomez, MD [clinicaltrials_resource:575358a23229afb2450da514f01938b2]Nestor Molfino, M.D. [clinicaltrials_resource:57edf68a67d87bcc34df6f5e206d56bb]Jessie Groothuis, MD [clinicaltrials_resource:5eb7871b122e5197e19650cb91c586c4]Dominic Lai, MD [clinicaltrials_resource:5f51e2d83d72f96dc8e0a47ec39f9d90]Joyson J Karakunnel, MD [clinicaltrials_resource:65b286890cb696886e068cf99166859c]Robert A. Gasser, Jr., M.D. [clinicaltrials_resource:65e474d0c367b7802ab50b033d3b30ad]Joseph Parker, M.D. [clinicaltrials_resource:6ac601bc727b95499475ec4dc4834be8]Medical Monitor [clinicaltrials_resource:6aefb22b9f7bb7c90aadc8f5a5ddb6b0]
affiliation [clinicaltrials_vocabulary:affiliation]
clinicaltrials:NCT00077493Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older [clinicaltrials:NCT00192153]Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months [clinicaltrials:NCT00192166]A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. [clinicaltrials:NCT00192179]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults [clinicaltrials:NCT00192192]Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children [clinicaltrials:NCT00192205]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) [clinicaltrials:NCT00192231]Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children [clinicaltrials:NCT00192244]Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma [clinicaltrials:NCT00192257]Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children [clinicaltrials:NCT00192270]Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers [clinicaltrials:NCT00192283]Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. [clinicaltrials:NCT00192309]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children [clinicaltrials:NCT00192322]A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants [clinicaltrials:NCT00192348]Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children [clinicaltrials:NCT00192374]Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T) [clinicaltrials:NCT00192387]Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children. [clinicaltrials:NCT00192400]Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza [clinicaltrials:NCT00192413]Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children. [clinicaltrials:NCT00192426]Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older [clinicaltrials:NCT00217230]Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults [clinicaltrials:NCT00224783]Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive [clinicaltrials:NCT00263744]A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia [clinicaltrials:NCT00586924]A Phase I,Multicenter, Dose Escalation Study of CAT-8015 in Patients With Chronic Leukemia [clinicaltrials:NCT00587457]clinicaltrials:NCT00626808A Study to Assess the Efficacy, Safety,and Tolerability of CAT-354 [clinicaltrials:NCT00640016]CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma [clinicaltrials:NCT00659425]clinicaltrials:NCT00808808clinicaltrials:NCT00945893clinicaltrials:NCT00946101A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Subjects With Systemic Lupus Erythematosus or Myositis [clinicaltrials:NCT00979654]A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis [clinicaltrials:NCT01050998]A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects [clinicaltrials:NCT01093040]clinicaltrials:NCT01127321A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis [clinicaltrials:NCT01209585]clinicaltrials:NCT01227278An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF [clinicaltrials:NCT01455402]clinicaltrials:NCT01579916Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis [clinicaltrials:NCT01585766]clinicaltrials:NCT01859143
collaborator [clinicaltrials_vocabulary:collaborator]
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma [clinicaltrials:NCT00066196]Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate [clinicaltrials:NCT00069017]MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer [clinicaltrials:NCT00072930]clinicaltrials:NCT00074048clinicaltrials:NCT00077493Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer [clinicaltrials:NCT00081315]Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00086099]Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia [clinicaltrials:NCT00105313]Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV) [clinicaltrials:NCT00111579]Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma [clinicaltrials:NCT00111696]Study to Evaluate MEDI-534 in Healthy Adults [clinicaltrials:NCT00111878]clinicaltrials:NCT00112112clinicaltrials:NCT00113490clinicaltrials:NCT00113880Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528 [clinicaltrials:NCT00116168]MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States [clinicaltrials:NCT00121108]Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease [clinicaltrials:NCT00123942]Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults [clinicaltrials:NCT00125944]BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma [clinicaltrials:NCT00126646]Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6–59 Months of Age [clinicaltrials:NCT00128167]clinicaltrials:NCT00129766Long-Term Follow-Up Study of Psoriasis Patients [clinicaltrials:NCT00131066]Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults [clinicaltrials:NCT00192127]Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age [clinicaltrials:NCT00192140]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older [clinicaltrials:NCT00192153]Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months [clinicaltrials:NCT00192166]A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. [clinicaltrials:NCT00192179]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults [clinicaltrials:NCT00192192]Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children [clinicaltrials:NCT00192205]Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program [clinicaltrials:NCT00192218]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) [clinicaltrials:NCT00192231]Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children [clinicaltrials:NCT00192244]Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma [clinicaltrials:NCT00192257]Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children [clinicaltrials:NCT00192270]Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers [clinicaltrials:NCT00192283]clinicaltrials:NCT00192296Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. [clinicaltrials:NCT00192309]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children [clinicaltrials:NCT00192322]Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants [clinicaltrials:NCT00192335]A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants [clinicaltrials:NCT00192348]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Robert A. Gasser, Jr., MD, MedImmune LLC [clinicaltrials_resource:107a75d60335ce8d5b64d5823e721ae3]Dirk J. Reitsma, M.D., MedImmune LLC [clinicaltrials_resource:2f04cb91e7f9d3d4e570013af0a3b200]Luz Hammershaimb, M.D., V.P., Clinical Dev., MedImmune LLC [clinicaltrials_resource:38bc9a43d464c87aa256c5b00ab4e428]Rayburn Mallory, M.D., MedImmune LLC [clinicaltrials_resource:420b00e85f00be99467f4f6c849d39ca]Elissa Malkin, D.O., MedImmune LLC [clinicaltrials_resource:555a2dafca82b63ade8922ab7d89e837]Hanaa Elhefni, MD, MS, MPH, MedImmune LLC [clinicaltrials_resource:5d4908cedfd0b931a50e8ee210e84f6c]Robert Walker, MD, MedImmune LLC [clinicaltrials_resource:5ff2c179eeda5b561c603b383c03a5b8]Margarita M Gomez, M.D., MedImmune LLC [clinicaltrials_resource:6c5e42b6461cb6ce7a9a26af9f40104d]Lawrence Danel-Moore, M.D., PhD, VP, Clin. Dev., MedImmune LLC [clinicaltrials_resource:754241863574a826fa8f96183a4c497b]Chris Ambrose, Dir. Medical Affairs, MedImmune LLC [clinicaltrials_resource:fa1f189240da3956604354601f682b63]
organization [clinicaltrials_vocabulary:organization]
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma [clinicaltrials:NCT00066196]Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate [clinicaltrials:NCT00069017]MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer [clinicaltrials:NCT00072930]clinicaltrials:NCT00074048clinicaltrials:NCT00077493Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer [clinicaltrials:NCT00081315]Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00086099]Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia [clinicaltrials:NCT00105313]Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV) [clinicaltrials:NCT00111579]Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma [clinicaltrials:NCT00111696]Study to Evaluate MEDI-534 in Healthy Adults [clinicaltrials:NCT00111878]clinicaltrials:NCT00112112clinicaltrials:NCT00113490clinicaltrials:NCT00113880Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528 [clinicaltrials:NCT00116168]MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States [clinicaltrials:NCT00121108]Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease [clinicaltrials:NCT00123942]Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults [clinicaltrials:NCT00125944]BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma [clinicaltrials:NCT00126646]Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6–59 Months of Age [clinicaltrials:NCT00128167]clinicaltrials:NCT00129766Long-Term Follow-Up Study of Psoriasis Patients [clinicaltrials:NCT00131066]Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults [clinicaltrials:NCT00192127]Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age [clinicaltrials:NCT00192140]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older [clinicaltrials:NCT00192153]Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months [clinicaltrials:NCT00192166]A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. [clinicaltrials:NCT00192179]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults [clinicaltrials:NCT00192192]Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children [clinicaltrials:NCT00192205]Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program [clinicaltrials:NCT00192218]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) [clinicaltrials:NCT00192231]Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children [clinicaltrials:NCT00192244]Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma [clinicaltrials:NCT00192257]Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children [clinicaltrials:NCT00192270]Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers [clinicaltrials:NCT00192283]clinicaltrials:NCT00192296Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. [clinicaltrials:NCT00192309]Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children [clinicaltrials:NCT00192322]Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants [clinicaltrials:NCT00192335]A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants [clinicaltrials:NCT00192348]
source [clinicaltrials_vocabulary:source]
MedImmune LLC [clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30]
Bio2RDF identifier
b51d23fca6b91c22d86a173e2ba65c30
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30
title
MedImmune LLC
@en
type
label
MedImmune LLC [clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30]
@en